GREENBIOCATALYST | NEW GENERATION OF BIOCATALYSTS FOR THE CHEMICAL INDUSTRY

Summary
A new generation of Biocatalyst is being studied and developed for the production of the fundamental acrylamide monomer used in a wide variety of fields like chemical, mining and textile, etc.
The Biocatalyst developed by Columbia, is completely environmental concerned, offering on top strong energetic savings. Such economic reductions will have a huge impacts and benefits on companies, which will have to switch from the actual energy intensive copper-based catalyst. The current method is extremely toxic for men and contain residues that greatly pollute the environment.
Columbia has been using non-GMOs and can truly impulse new job creation in Europe, as it will be the very first biocatalyst made and developed within the EU. It will eventually break down the actual monopolism of the only two Japanese manufacturers that sell biocats on exclusive way.
An international patent guarantees Columbia’s innovation providing credibility and continuity to the project, which require high capital investments.
In few words the impact of biocatalysts in the future will be precisely this: the increasing ability to use enzymes to catalyze chemical reactions in industrial processes, including the production of drug substances, flavors, fragrances, electronic chemicals, polymers—chemicals that literally impact almost every facet of our life. In adopting biocatalysts as a mainstream technology for chemical production, we will be introducing a technology that is greener, reduces pollution and cost, and creates greater sustainability.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/744952
Start date: 01-12-2016
End date: 31-05-2017
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

A new generation of Biocatalyst is being studied and developed for the production of the fundamental acrylamide monomer used in a wide variety of fields like chemical, mining and textile, etc.
The Biocatalyst developed by Columbia, is completely environmental concerned, offering on top strong energetic savings. Such economic reductions will have a huge impacts and benefits on companies, which will have to switch from the actual energy intensive copper-based catalyst. The current method is extremely toxic for men and contain residues that greatly pollute the environment.
Columbia has been using non-GMOs and can truly impulse new job creation in Europe, as it will be the very first biocatalyst made and developed within the EU. It will eventually break down the actual monopolism of the only two Japanese manufacturers that sell biocats on exclusive way.
An international patent guarantees Columbia’s innovation providing credibility and continuity to the project, which require high capital investments.
In few words the impact of biocatalysts in the future will be precisely this: the increasing ability to use enzymes to catalyze chemical reactions in industrial processes, including the production of drug substances, flavors, fragrances, electronic chemicals, polymers—chemicals that literally impact almost every facet of our life. In adopting biocatalysts as a mainstream technology for chemical production, we will be introducing a technology that is greener, reduces pollution and cost, and creates greater sustainability.

Status

CLOSED

Call topic

SMEInst-03-2016-2017

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.4. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
H2020-SMEINST-1-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market
H2020-SMEINST-2-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-1-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market
H2020-SMEINST-2-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market